熱門資訊> 正文
礼来公司因每周一次的胰岛素产品获得FDA认可Onswik
2026-09-24 19:07
- Eli Lilly (LLY) on Thursday announced that the U.S. FDA approved its once-weekly basal insulin product, Onswik, for adults with type 2 diabetes to be used with diet and exercise for the control of high blood sugar.
- The decision is supported by data from the company’s QWINT Phase 3 clinical trials in which Onswik reached the primary endpoint, showing a comparable efficacy level to once-daily insulin products, insulin glargine U-100 (glargine), or insulin degludec U-100 (degludec).
- According to the Indiana-based pharma giant, Onswik has the potential to cut more than 300 insulin injections annually compared with once-daily basal insulin. The decision marked the fourth global regulatory action favoring the product after similar approvals in Europe, Mexico, and Japan.
- The company expects to launch Onswik in the coming months in two concentrations: 500 units/mL and 1,000 units/mL.
More on Eli Lilly
- Eli Lilly Vs. Novo Nordisk: Temporarily Cheap Or Correctly Cheap?
- Eli Lilly and Company (LLY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- Eli Lilly Stock Is Not Done Growing Yet, But It's Due For Compression (Rating Downgrade)
- InnoCare inks licensing deal with Eli Lilly worth up to $3.35B
- Nektar Therapeutics drops as jury deliberates in Eli Lilly dispute over Rezpeg
推薦文章
美股前瞻 | 聯儲局再傳「鷹聲」！美債收益率應聲走高，納指期貨跌近1%；中美第八輪經貿磋商達成多項共識；Meta全面押注個人Agent
一周財經日曆 | 影響加息大事！9月大小非農數據重磅登場；美光、希音齊放榜！景旺電子、歡創科技等5只新股下周上市
Q4淨利或狂飆逾1000%！美光能否交出」炸裂「財報？三大焦點將影響股價走向
休市提醒：中秋假期來臨，港股9月25日（周五）正常開市
華盛早報 | 強勁PMI催高加息預期！納指回調1%；美財政部擬再回購60億美元長債；SpaceX總裁套現逾5200萬美元
美股前瞻 | 特朗普最新調倉曝光！拋售微軟，買入英偉達；Meta科技盛會重磅來襲；高盛、德銀齊看多：標普500將衝刺8000點
特朗普重新定義AI：美國今后將把人工智能稱為「超級智能」
特朗普將亮相聯大：聚焦伊朗 密集會見多國領導人 計劃與丹麥簽署協議
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
